Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and dostarlimab in pediatric recurrent/refractory solid tumors
NCT04544995Phase 1Terminated
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib and dostarlimab in osteosarcoma (OS), neuroblastoma, adrenocortical carcinoma (ACC) and 3 more (5 arms), sponsored by GSK. Primary endpoints: Dose-limiting Toxicities at 42 days, Grade ≥3 Thrombocytopenia Adverse Events at 42 days and 2 more. Started Oct 2020; status: terminated.
02
Drugs
niraparibdostarlimab
03
Conditions
osteosarcoma (OS)neuroblastomaadrenocortical carcinoma (ACC)Ewing sarcomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04544995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544995.